Noble Capital Markets Initiates Coverage on Zomedica

Zomedica Corp., a veterinary health company, announced that Noble Capital Markets has begun equity research coverage on the company. This development could bring increased visibility to Zomedica's financial health and market potential, as the detailed report is now accessible through Channelchek.

Known for their therapeutic and diagnostic solutions for animals, Zomedica's notable products include the PulseVet shock wave system and the TRUFORMA diagnostic platform. With a strong presence in the U.S. market valued at over $2 billion, the company reported a 33% revenue increase in 2023, reaching $25 million.

Zomedica’s strategic focus includes expanding its product offerings and international presence. With $78 million in liquidity as of September 2024, the company aims to enhance veterinary practice profitability and care quality for pets.